-
公开(公告)号：US20040204480A1
公开(公告)日：2004-10-14
申请号：US10790943
申请日：2004-03-02
发明人： William R. Wilson , Bronwyn G. Siim
IPC分类号： A61K031/353 , A61K031/7072 , A61K031/7048 , A61K031/704
CPC分类号： A61K31/66 , A61K31/352 , A61K31/4353 , A61K31/475 , A61K31/505 , A61K31/65 , A61K31/70 , A61K31/7034 , A61K33/24 , A61K2300/00
摘要： The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.
摘要翻译： 本发明涉及化合物5,6-二甲基呫吨酮-4-乙酸（DMXAA）与选自铂化合物，长春花生物碱，烷化剂，蒽环类，拓扑异构酶I抑制剂，抗代谢物和拓扑异构酶II抑制剂的化合物的协同组合，其中 具有抗肿瘤活性。 优选地，本发明涉及化合物5,6-二甲基呫吨酮-4-乙酸（DMXAA）和选自卡铂，吉西他滨，顺铂，5-氟尿嘧啶，环磷酰胺，依托泊苷，长春新碱，多柔比星和伊立替康的化合物的协同组合。 更具体地，本发明涉及这样的组合在治疗癌症中的用途以及含有这些组合的药物组合物。 本发明进一步提供了制备本发明组合的方法。
-
公开(公告)号：US20030211521A1
公开(公告)日：2003-11-13
申请号：US10334726
申请日：2003-01-02
IPC分类号： C12Q001/68 , G01N033/574 , C07H021/04 , C12P021/02 , C12N005/06 , C07K014/47 , C07K016/30
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , A61K48/00 , A61K2039/51
摘要： A gene encoding a polypeptide, related in sequence to retinoblastoma binding proteins 1 and 2, which is expressed in breast cancer, therapeutic and diagnostic methods relating to this gene and polypeptide.
摘要翻译： 编码与乳腺癌中表达的视网膜母细胞瘤结合蛋白1和2的序列相关的多肽的基因，与该基因和多肽相关的治疗和诊断方法。
-
83.发明授权
公开(公告)号：US5885808A
公开(公告)日：1999-03-23
申请号：US428257
申请日：1995-07-05
IPC分类号： C12N15/09 , A61K31/70 , A61K35/76 , A61K38/00 , A61K38/16 , A61K38/21 , A61K38/45 , A61K38/46 , A61K48/00 , C07K14/075 , C07K16/00 , C12N7/00 , C12N7/04 , C12N15/13 , C12N15/34 , C12N15/86 , C12N15/861 , C12N15/87 , A61K39/235
CPC分类号： C12N7/00 , A61K48/00 , C07K14/005 , C07K16/00 , C12N15/86 , C12N15/87 , A61K38/00 , C07K2319/00 , C07K2319/035 , C07K2319/33 , C12N2710/10322 , C12N2710/10323 , C12N2710/10343 , C12N2710/10345 , C12N2810/854 , C12N2810/859 , C12N2830/008
摘要： An adenovirus or adenovirus-like particle which has a modified binding specificity conferred by a binding moiety. The binding moiety is heterologous to the adenovirus and is incorporated as a fusion protein with the fiber protein. This allows the adenovirus or adenovirus-like particle to bind to a target cell which is not the natural host cell of the virus. The penton fiber is modified by the insertion or, deletion, or substitution of amino acid residues, that disrupt the host-cell binding function so that the adenovirus or adenovirous like particle does not bind the natural host cell.
摘要翻译： PCT No.PCT / GB93 / 02267 Sec。 371日期：1995年7月5日 102（e）日期1995年7月5日PCT 1993年11月4日PCT公布。 WO94 / 10323 PCT出版物 日期1994年5月11日具有由结合部分赋予的修饰的结合特异性的腺病毒或腺病毒样颗粒。 结合部分与腺病毒是异源的，并且作为与纤维蛋白质的融合蛋白结合。 这允许腺病毒或腺病毒样颗粒结合到不是病毒的天然宿主细胞的靶细胞。 通过插入或删除或取代氨基酸残基修饰五邻体纤维，破坏宿主细胞结合功能，使得腺病毒或腺苷样颗粒不结合天然宿主细胞。
-
公开(公告)号：US12129236B2
公开(公告)日：2024-10-29
申请号：US17204206
申请日：2021-03-17
发明人： Alison E. McGonagle , Allan M. Jordan , Bohdan Waszkowycz , Colin P. Hutton , Ian D. Waddell , James R. Hitchin , Kate M. Smith , Niall M. Hamilton
IPC分类号： C07D235/26 , A61P35/00 , C07D307/85 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D409/04 , C07D413/04 , C07D413/06 , C07D413/14 , C07D417/04 , C07D417/06 , C07D417/14
CPC分类号： C07D235/26 , A61P35/00 , C07D307/85 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D409/04 , C07D413/04 , C07D413/06 , C07D413/14 , C07D417/04 , C07D417/06 , C07D417/14
摘要： The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity: wherein R1a, R1b, R1c, R1d, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.
-
公开(公告)号：US12109184B2
公开(公告)日：2024-10-08
申请号：US17338283
申请日：2021-06-03
发明人： Oliver D.K. Maddocks
IPC分类号： A61K31/198 , A61P35/00
CPC分类号： A61K31/198 , A61P35/00
摘要： Disclosed herein are dietary compositions that are substantially devoid of at least cysteine or a salt thereof for use in treating a cancer. The dietary compositions and methods of the disclosure can be used to treat cancers that are MTAP-deficient, alone or in combination with a cancer therapy.
-
公开(公告)号：US20240309101A1
公开(公告)日：2024-09-19
申请号：US18470875
申请日：2023-09-20
发明人： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Mark Brown , Sergio Quezada , James Geoghegan , Bianka Prinz
IPC分类号： C07K16/28 , A61K39/00 , A61K39/395 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/05 , C07K14/55 , C12N15/85
CPC分类号： C07K16/2866 , A61K39/39533 , A61K39/39541 , A61K39/39558 , A61K39/39566 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/05 , C07K14/55 , C07K16/2818 , C07K16/2827 , C12N15/85 , A61K2039/505 , A61K2039/507 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/60 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C12N2015/8518
摘要： The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
-
公开(公告)号：US12077526B2
公开(公告)日：2024-09-03
申请号：US18159452
申请日：2023-01-25
发明人： Steven Howard , Benjamin David Cons , Jeffrey David St. Denis , Rhian Sara Holvey , Guillaume François Parra , Kim Louise Hirst , Isabelle Anne Lemasson , David John Nash , James Daniel Osborne , Jonas Calleja Priede , Nicholas Paul Richards , Aaron Michael Dumas , Brian Christopher Bishop , David Parry-Jones , Meenakshi Sundaram Shanmugham , Darren James Dixon , Matthew James Gaunt
IPC分类号： C07D405/06
CPC分类号： C07D405/06 , C07B2200/13
摘要： The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.
-
88.发明授权公开(公告)号：US11919959B2
公开(公告)日：2024-03-05
申请号：US16992497
申请日：2020-08-13
发明人： Roy Bicknell , Peter Noy , Kabir Ali Khan
CPC分类号： C07K16/2851 , A01K67/0278 , A61P35/00 , C07K16/30 , G01N33/5008 , A01K2217/075 , A01K2227/105 , A01K2267/0375 , A61K2039/505 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/70 , C07K2317/76
摘要： The invention provides a method of inhibiting angiogenesis in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMRN2. The inhibitor may be an antibody, a polypeptide, a peptide, a polynucleotide, a peptidomimetic, a natural product, a carbohydrate, an aptamer or a small molecule.
-
公开(公告)号：US20240062898A1
公开(公告)日：2024-02-22
申请号：US18007670
申请日：2021-06-04
摘要： The present invention provides methods for predicting the treatment response of a cancer patient, using a tumour copy number profile for the patient. The method comprise analysing the copy number profile to assess whether the characteristics of at least one copy number feature are indicative of the presence of focal amplifications in the tumour genome, wherein the at least one copy number feature is selected from: copy number change-point, segment size and segment copy number. The patient is predicted as being likely to be resistant to treatment with an agent that induces the formation of micronuclei (e.g. doxorubicin) if the characteristics of the at least one copy number features are indicative of the presence of focal amplifications in the tumour genome. Also provided a related methods and systems.
-
公开(公告)号：US11879014B2
公开(公告)日：2024-01-23
申请号：US16494962
申请日：2018-03-03
发明人： Anne Goubier , Josephine Salimu , Kevin Moulder , Beatriz Goyenechea Corzo , Pascal Merchiers , Sergio Quezada , Karl Peggs , Frederick Arce Vargas , Isabelle Solomon
CPC分类号： C07K16/2866 , C07K14/55 , C07K16/2818 , A61K39/0011 , A61K45/06 , C07K2317/31 , C07K2317/52 , C07K2317/60 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2-CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.
-
-
-
-
-
-
-
-
-
搜索结果
438 条记录 (耗时 0.04 秒)
